BSE: 541400 | NSE: ZIMLAB | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zim Laboratories Ltd is a average quality company.
The key valuation ratios of Zim Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zim Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation Index Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -8.4% | 10% | 14.2% | 16.1% | 15% | 4.8% | 8.1% | 12% | 17.5% | 10.1% | - |
| Value Creation Index ⓘ | -1.6 | -0.3 | 0.0 | 0.2 | 0.1 | -0.7 | -0.4 | -0.1 | 0.3 | -0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 266 | 268 | 235 | 272 | 332 | 274 | 304 | 329 | 397 | 365 | 385 |
| Sales YoY Gr. | - | 0.7% | -12.4% | 15.7% | 22% | -17.3% | 10.7% | 8.5% | 20.4% | -7.8% | - |
| Adj EPS ⓘ | 0.2 | 1.7 | 3.7 | 2.7 | 3.2 | 0.1 | 1.7 | 2.1 | 4.3 | 2.9 | 2.9 |
| YoY Gr. | - | 663.6% | 118.5% | -27.5% | 19.2% | -98.1% | 2700% | 25% | 106.2% | -33% | - |
| BVPS (₹) ⓘ | 19.6 | 20.5 | 24.5 | 28 | 31 | 31.2 | 32.2 | 34.9 | 39.9 | 47.6 | 49 |
| Adj Net Profit ⓘ | 1.1 | 8.1 | 17.7 | 12.9 | 15.3 | 0.3 | 8.2 | 10.2 | 21.1 | 14.1 | 14 |
| Cash Flow from Ops. ⓘ | 5.5 | 22.1 | 32.1 | 36.7 | 37.1 | 21.3 | 31.9 | 47 | 35.2 | 11.5 | - |
| Debt/CF from Ops. ⓘ | 17 | 4.4 | 2.5 | 2.2 | 2.1 | 4.2 | 2.5 | 1.1 | 1.7 | 9.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 3.6% | 2% | 6.4% | -7.8% | ||||
| Adj EPS ⓘ | 33.2% | -1.8% | 20% | -33% | ||||
| BVPSⓘ | 10.3% | 8.9% | 13.9% | 19.5% | ||||
| Share Price | - | 33.4% | 17.6% | -20% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1 | 8.3 | 16.3 | 10.1 | 10.7 | 0.2 | 5.3 | 6.3 | 11.6 | 6.6 | 6.1 |
| Op. Profit Mgn % ⓘ | 8 | 11.1 | 13.5 | 12.5 | 12.9 | 7.2 | 12.1 | 11.5 | 12.9 | 11 | 11.3 |
| Net Profit Mgn % ⓘ | 0.4 | 3 | 7.5 | 4.7 | 4.6 | 0.1 | 2.7 | 3.1 | 5.3 | 3.9 | 3.7 |
| Debt to Equity ⓘ | 1 | 1 | 0.7 | 0.6 | 0.5 | 0.6 | 0.5 | 0.3 | 0.3 | 0.5 | - |
| Working Cap Days ⓘ | 217 | 212 | 233 | 226 | 215 | 258 | 225 | 222 | 188 | 215 | 86 |
| Cash Conv. Cycle ⓘ | 87 | 80 | 104 | 89 | 68 | 79 | 52 | 60 | 58 | 95 | 23 |
Net Profit is growing at healthy rate in last 3 years 19.96%
Return on Equity has declined versus last 3 years average to 6.00%
Sales growth has been subdued in last 3 years 6.37%
Sales growth is not so good in last 4 quarters at 9.89%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.9 | 3.2 |
| TTM Sales (₹ Cr.) | 385 | 388 |
| BVPS (₹.) ⓘ | 49 | 50.6 |
| Reserves (₹ Cr.) ⓘ | 190 | 198 |
| P/BV ⓘ | 1.68 | 1.63 |
| PE ⓘ | 28.28 | 26.16 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 81.72 / 131.30 |
| All Time Low / High (₹) | 14.00 / 151.75 |
| Market Cap (₹ Cr.) | 402 |
| Equity (₹ Cr.) | 48.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 37.5 |
| Mar'24 | YoY Gr. Rt. % | Jun'24 | YoY Gr. Rt. % | Sep'24 | YoY Gr. Rt. % | Dec'24 | YoY Gr. Rt. % | |
|---|---|---|---|---|---|---|---|---|
| Sales (₹ Cr.)ⓘ | 117 | 12.4 | 82 | 22.4 | 89.7 | 5.2 | 95.4 | -0.5 |
| Adj EPS (₹) ⓘ | 1.6 | 10.2 | 0.2 | N/A | 0.3 | -70.9 | 0.9 | -10.1 |
| Op. Profit Mgn % ⓘ | 13.14 | -127 bps | 9.61 | 284 bps | 9.35 | -116 bps | 12.33 | 67 bps |
| Net Profit Mgn % ⓘ | 6.72 | -12 bps | 0.93 | 114 bps | 1.36 | -354 bps | 4.56 | -48 bps |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Company Name | CMP(₹) | |||||||
|---|---|---|---|---|---|---|---|---|
| Alembic Pharma | 828 | 22.5 (2.8%) | Small Cap | 6,229 | 30.8 | 9.6 | 26.2 | 3.2 |
| Laurus Labs | 573.5 | -10.8 (-1.9%) | Small Cap | 5,041 | 3.7 | 3.1 | 157.3 | 7.5 |
| Piramal Pharma | 201.9 | -0.1 (-0%) | Small Cap | 4,390 | 5.2 | 8.4 | 39 | 3.8 |
| Ajanta Pharma | 2,541.2 | -3.7 (-0.2%) | Small Cap | 4,209 | 71.9 | 19 | 35.4 | 8.1 |
| Gland Pharma | 1,554.2 | -23.6 (-1.5%) | Small Cap | 4,167 | 68.1 | 24.8 | 23.2 | 2.8 |
| Natco Pharma | 780.8 | -3.3 (-0.4%) | Small Cap | 3,999 | 104.1 | 34.5 | 7.5 | 1.9 |
| Granules India | 471.2 | -4.6 (-1%) | Small Cap | 3,755 | 13.3 | 11.7 | 35.8 | 3.5 |
| Emcure Pharma | 926.4 | 0 (0%) | Small Cap | 3,498 | 8.5 | 4.4 | 109.1 | 6.1 |
| JB Chem & Pharma | 1,518 | 13.3 (0.9%) | Small Cap | 3,299 | 40.4 | 16.1 | 37.3 | 7.1 |
| Sanofi India | 5,587.9 | 32.6 (0.6%) | Small Cap | 2,851 | 136.2 | 20.8 | 40.8 | 14.9 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 268 | 235 | 272 | 332 | 274 | 304 | 329 | 397 | 365 |
| Operating Expenses ⓘ | 245 | 239 | 203 | 238 | 289 | 255 | 267 | 292 | 345 | 325 |
| Manufacturing Costs | 33 | 14 | 13 | 14 | 21 | 34 | 30 | 38 | 45 | 53 |
| Material Costs | 162 | 157 | 120 | 141 | 160 | 143 | 159 | 160 | 199 | 171 |
| Employee Cost | 23 | 31 | 33 | 41 | 48 | 35 | 34 | 39 | 46 | 51 |
| Other Costs ⓘ | 27 | 37 | 37 | 43 | 61 | 42 | 43 | 54 | 55 | 50 |
| Operating Profit ⓘ | 21 | 29 | 32 | 34 | 42 | 20 | 37 | 38 | 51 | 40 |
| Operating Profit Margin (%) | 8.0% | 10.9% | 13.4% | 12.5% | 12.8% | 7.2% | 12.1% | 11.5% | 12.9% | 11.0% |
| Other Income ⓘ | 2 | 4 | 6 | 3 | 2 | 5 | 2 | 5 | 6 | 5 |
| Interest ⓘ | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 |
| Depreciation ⓘ | 7 | 9 | 9 | 10 | 11 | 13 | 15 | 15 | 16 | 15 |
| Exceptional Items ⓘ | -33 | -5 | 0 | 6 | 0 | 0 | -5 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -27 | 5 | 18 | 24 | 23 | -1 | 9 | 19 | 36 | 23 |
| Tax ⓘ | -5 | 0 | -1 | 6 | 7 | -3 | 3 | 6 | 11 | 6 |
| Profit After Tax | -22 | 5 | 19 | 18 | 16 | 2 | 6 | 13 | 25 | 17 |
| PAT Margin (%) | -8.1% | 1.9% | 7.9% | 6.7% | 4.8% | 0.6% | 1.8% | 3.9% | 6.3% | 4.6% |
| Adjusted EPS (₹) | -4.5 | 1.1 | 3.9 | 3.8 | 3.3 | 0.4 | 1.2 | 2.7 | 5.1 | 3.4 |
| Dividend Payout Ratio (%) | 0% | 16% | 2% | 2% | 5% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 94 | 98 | 118 | 135 | 150 | 151 | 157 | 170 | 194 | 232 |
| Share Capital ⓘ | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 |
| Reserves ⓘ | 86 | 90 | 110 | 127 | 134 | 135 | 141 | 154 | 145 | 183 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 89 | 91 | 74 | 70 | 62 | 77 | 66 | 36 | 48 | 91 |
| Long Term Debt | 38 | 35 | 28 | 20 | 22 | 27 | 22 | 19 | 25 | 36 |
| Short Term Debt | 51 | 56 | 47 | 50 | 40 | 50 | 45 | 17 | 23 | 55 |
| Trade Payables | 64 | 47 | 45 | 66 | 72 | 66 | 65 | 82 | 59 | 63 |
| Others Liabilities ⓘ | 19 | 21 | 13 | 22 | 40 | 23 | 29 | 49 | 40 | 57 |
| Total Liabilities ⓘ | 266 | 257 | 250 | 294 | 324 | 318 | 318 | 337 | 341 | 443 |
Fixed Assets | ||||||||||
| Gross Block | 108 | 120 | 98 | 113 | 130 | 153 | 160 | 174 | 192 | 260 |
| Accumulated Depreciation | 20 | 28 | 9 | 19 | 29 | 42 | 56 | 71 | 85 | 100 |
| Net Fixed Assetsⓘ | 87 | 92 | 89 | 94 | 101 | 111 | 103 | 103 | 107 | 160 |
| CWIP ⓘ | 6 | 3 | 4 | 8 | 13 | 10 | 10 | 11 | 26 | 40 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 5 | 8 | 8 | 8 | 8 | 8 |
| Inventories | 46 | 38 | 35 | 52 | 55 | 56 | 54 | 75 | 54 | 81 |
| Trade Receivables | 81 | 89 | 88 | 88 | 90 | 63 | 64 | 81 | 88 | 100 |
| Cash Equivalents | 8 | 6 | 6 | 4 | 3 | 3 | 8 | 2 | 2 | 1 |
| Others Assetsⓘ | 38 | 30 | 28 | 48 | 57 | 66 | 70 | 56 | 55 | 51 |
| Total Assets ⓘ | 266 | 257 | 250 | 294 | 324 | 318 | 318 | 337 | 341 | 443 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 5 | 22 | 32 | 37 | 37 | 21 | 32 | 47 | 35 | 11 |
| PBT ⓘ | -27 | 5 | 18 | 24 | 23 | -1 | 14 | 19 | 36 | 23 |
| Adjustment ⓘ | 51 | 29 | 21 | 13 | 24 | 25 | 25 | 21 | 21 | 21 |
| Changes in Working Capital ⓘ | -17 | -11 | -4 | 4 | -8 | 3 | -5 | 7 | -15 | -30 |
| Tax Paid ⓘ | -2 | -1 | -2 | -4 | -1 | -5 | -1 | 0 | -7 | -3 |
| Cash Flow From Investing Activity ⓘ | -9 | -12 | -7 | -26 | -23 | -19 | -6 | -14 | -35 | -72 |
| Capex | -15 | -13 | -9 | -28 | -18 | -15 | -6 | -15 | -36 | -73 |
| Net Investments | 0 | 1 | 1 | 2 | -1 | -1 | 0 | 0 | 0 | 1 |
| Others ⓘ | 6 | 0 | 0 | 0 | -4 | -3 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -3 | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -3 | -4 | -5 | -3 | 5 | 4 | -4 | -3 | 3 | 15 |
| Interest Paid ⓘ | -10 | -12 | -10 | -9 | -10 | -14 | -10 | -8 | -6 | -8 |
| Dividend Paid ⓘ | -1 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 |
| Others ⓘ | 11 | 5 | -10 | 3 | -9 | 9 | -11 | -22 | 3 | 52 |
| Net Cash Flow ⓘ | -7 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 1 | -1 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -20.51 | 5.34 | 17.27 | 14.45 | 11.22 | 1.16 | 3.64 | 7.96 | 13.73 | 7.86 |
| ROCE (%) | -8.39 | 9.97 | 14.24 | 16.08 | 14.96 | 4.75 | 8.12 | 12.02 | 17.48 | 10.13 |
| Asset Turnover Ratio | 1.04 | 1.06 | 0.95 | 1.01 | 1.07 | 0.86 | 0.96 | 1.01 | 1.17 | 0.93 |
| PAT to CFO Conversion(x) | N/A | 4.4 | 1.68 | 2.06 | 2.31 | 10.5 | 5.33 | 3.62 | 1.4 | 0.65 |
| Working Capital Days | ||||||||||
| Receivable Days | 119 | 112 | 134 | 118 | 98 | 102 | 77 | 80 | 78 | 94 |
| Inventory Days | 51 | 55 | 55 | 58 | 59 | 74 | 67 | 72 | 59 | 67 |
| Payable Days | 125 | 129 | 140 | 144 | 158 | 176 | 151 | 167 | 130 | 130 |
ZIM Laboratories Limited is a public limited company domiciled in India engaged in the manufacturing of formulation on drugs. The company also has wholly owned subsidiaries (Zim Laboratories FZE,UAE , SIA Zim Laboratories Limited, Latvia and Zim Health Technologies Limited, India) (the Company and its subsidiaries are together referred to as 'the Group') which are engaged in manufacturing & wholesale of pharmaceutical products, market research and research & development activities.
Business area of the company
The company is engaged in the manufacturing of formulation on drugs and pre formulation on ingredients in India and marketing and selling these within and outside India.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
